New treatment approach for heart and metabolic issues in people with HIV
Lipid raft therapy – a novel therapeutic approach for HIV-associated cardiometabolic co-morbidities
This study is looking at how a specific HIV protein can cause heart and metabolic issues in people living with HIV, even if they're on treatment, and aims to find new ways to help improve their health by understanding how this protein affects cholesterol in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10817675 on NIH RePORTER |
What this research studies
This research investigates how HIV infection leads to heart and metabolic problems, even in patients who are on effective antiretroviral therapy. It focuses on a specific HIV protein called Nef, which disrupts cholesterol metabolism and contributes to these complications. By studying how Nef affects lipid rafts in cells, the researchers aim to develop therapies that can reverse these harmful changes and improve patient health. The approach involves analyzing extracellular vesicles that carry Nef and understanding their role in inflammation and cholesterol metabolism.
Who could benefit from this research
Good fit: Ideal candidates for this research are HIV-infected individuals who are on antiretroviral therapy but still experience cardiovascular and metabolic complications.
Not a fit: Patients who are not HIV-infected or those who do not have cardiovascular or metabolic issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that alleviate heart and metabolic issues in HIV-infected individuals.
How similar studies have performed: Other research has shown promising results in targeting similar mechanisms in HIV-related complications, suggesting potential for success in this novel approach.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Bukrinsky, Michael Ilya — George Washington University
- Study coordinator: Bukrinsky, Michael Ilya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.